DK1695714T3 - Genetisk manipuleret herpesvirus til behandling af tumorer - Google Patents

Genetisk manipuleret herpesvirus til behandling af tumorer

Info

Publication number: DK1695714T3
Authority: DK; Denmark
Prior art keywords: tumors; treatment; genetically engineered; herpes virus; engineered herpes
Prior art date: 1999-02-05

Application number

DK06009428T

Other languages

English (en)

Inventor

Ralph Weichselbaum

Bernard Roizman

Richard Whitley

Original Assignee

Arch Dev Corp

Uab Research Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-05

Filing date

2000-02-04

Publication date

2008-11-10

2000-02-04 Application filed by Arch Dev Corp, Uab Research Foundation filed Critical Arch Dev Corp

2008-11-10 Application granted granted Critical

2008-11-10 Publication of DK1695714T3 publication Critical patent/DK1695714T3/da

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
241001529453 unidentified herpesvirus Species 0.000 title 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
241000700584 Simplexvirus Species 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Mycology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK06009428T 1999-02-05 2000-02-04 Genetisk manipuleret herpesvirus til behandling af tumorer DK1695714T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24474899A	1999-02-05	1999-02-05
PCT/US2000/002814 WO2000045853A2 (en)	1999-02-05	2000-02-04	Treatment of tumors with genetically engineered herpes virus

Publications (1)

Publication Number	Publication Date
DK1695714T3 true DK1695714T3 (da)	2008-11-10

Family

ID=22923971

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06009428T DK1695714T3 (da)	1999-02-05	2000-02-04	Genetisk manipuleret herpesvirus til behandling af tumorer

Country Status (10)

Country	Link
US (3)	US20030207829A9 (da)
EP (2)	EP1150696B1 (da)
JP (1)	JP4623832B2 (da)
AT (2)	ATE402713T1 (da)
AU (2)	AU772471B2 (da)
CA (1)	CA2361892C (da)
DE (2)	DE60027870T2 (da)
DK (1)	DK1695714T3 (da)
ES (2)	ES2310382T3 (da)
WO (1)	WO2000045853A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7780962B2 (en)	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
US7470426B1 (en)	1997-10-09	2008-12-30	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
IL145899A0 (en)	1999-04-15	2002-07-25	Pro Virus Inc	Treatment of neoplasms with viruses
US8147822B1 (en)	1999-09-17	2012-04-03	Wellstat Biologics Corporation	Oncolytic virus
AUPQ425699A0 (en)	1999-11-25	1999-12-23	University Of Newcastle Research Associates Limited, The	A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
EP2213300B1 (en) *	2001-05-09	2015-03-25	Takara Bio, Inc.	Composition and method for treating cancer using herpes virus
CA2476724A1 (en) *	2002-03-01	2003-09-12	Sloan-Kettering Institute For Cancer Research	Prevention of recurrence and metastasis of cancer
JP2004099584A (ja) *	2002-05-02	2004-04-02	Keio Gijuku	Ｈｓｖを用いた抗腫瘍剤
EP1549339B1 (en)	2002-10-07	2019-06-05	University Of Chicago	Targeting of herpes simplex virus to specific receptors
AU2002953436A0 (en)	2002-12-18	2003-01-09	The University Of Newcastle Research Associates Limited	A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2006002394A2 (en)	2004-06-24	2006-01-05	New York University	Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP2144632B1 (en) *	2007-05-09	2016-11-16	Board of Supervisors of Louisiana State University and Agricultural and Mechanical College	Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2009148488A2 (en) *	2008-05-29	2009-12-10	The General Hospital Corporation	Use of oncolytic herpes viruses for killing cancer stem cells
WO2016201450A2 (en) *	2015-06-11	2016-12-15	University Of Miami	Cancer treatment and diagnosis
AU2016403583B2 (en) *	2016-04-22	2020-05-28	Immvira Co., Limited	Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
TWI666321B (zh) *	2017-10-23	2019-07-21	大陸商深圳市亦諾微醫藥科技有限公司	用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構
KR101974169B1 (ko) *	2018-08-10	2019-04-30	의료법인 성광의료재단	재조합 단순 헤르페스 바이러스 및 이의 제조방법
KR102834430B1 (ko) *	2019-08-16	2025-07-15	임비라 컴퍼니 리미티드	전신 투여용 종양용해성 단순 포진 바이러스를 포함하는 약학적 조성물
EP4075980B1 (en)	2019-12-18	2025-07-23	Stinginn LLC	Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en)	2020-04-30	2024-02-13	Stinginn Llc	Small molecular inhibitors of sting signaling compositions and methods of use
JP7235334B2 (ja) *	2020-11-26	2023-03-08	イムヴィラ・カンパニー・リミテッド	癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
US20240024392A1 (en) *	2020-12-04	2024-01-25	Immvira Co., Limited	Oncolytic herpes simplex type 1 viruses for treatment of brain tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4769331A (en) *	1981-09-16	1988-09-06	University Patents, Inc.	Recombinant methods and materials
US4859587A (en) *	1984-06-04	1989-08-22	Institut Merieux	Recombinant herpes simplex viruses, vaccines and methods
US5288641A (en) *	1984-06-04	1994-02-22	Arch Development Corporation	Herpes Simplex virus as a vector
US5068192A (en) *	1986-01-27	1991-11-26	Prutech Research And Development Partnership	Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US4999296A (en) *	1986-04-29	1991-03-12	Novagene, Inc.	Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same
CA2039921A1 (en)	1990-04-16	1991-10-17	Xandra O. Breakefield	Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) *	1990-09-10	1994-07-12	Arch Development Corporation	Recombinant herpes simplex viruses vaccines and methods
US5360893A (en) *	1992-07-20	1994-11-01	University Of Colorado Foundation, Inc.	DNA sequences encoding proteins used to elicit and detect programmed cell death
US5593879A (en) *	1993-01-15	1997-01-14	Massachusetts Institute Of Technology	Cell death genes of Drosophila melanogaster and vertebrate analogs
US5585096A (en) *	1994-06-23	1996-12-17	Georgetown University	Replication-competent herpes simplex virus mediates destruction of neoplastic cells
ATE241994T1 (de) *	1996-01-25	2003-06-15	Univ Glasgow	Hsv-mutant-1716 zur behandlung von mesotheliomen
CA2200633A1 (en) *	1997-03-21	1998-09-21	Yuman Fong	Rapid production of autologous tumor vaccines

2000
- 2000-02-04 AT AT06009428T patent/ATE402713T1/de active
- 2000-02-04 EP EP00908465A patent/EP1150696B1/en not_active Expired - Lifetime
- 2000-02-04 EP EP06009428A patent/EP1695714B1/en not_active Expired - Lifetime
- 2000-02-04 AU AU29800/00A patent/AU772471B2/en not_active Ceased
- 2000-02-04 JP JP2000596972A patent/JP4623832B2/ja not_active Expired - Fee Related
- 2000-02-04 DE DE60027870T patent/DE60027870T2/de not_active Expired - Lifetime
- 2000-02-04 WO PCT/US2000/002814 patent/WO2000045853A2/en not_active Ceased
- 2000-02-04 ES ES06009428T patent/ES2310382T3/es not_active Expired - Lifetime
- 2000-02-04 AT AT00908465T patent/ATE325615T1/de active
- 2000-02-04 CA CA2361892A patent/CA2361892C/en not_active Expired - Fee Related
- 2000-02-04 DE DE60039730T patent/DE60039730D1/de not_active Expired - Lifetime
- 2000-02-04 DK DK06009428T patent/DK1695714T3/da active
- 2000-02-04 ES ES00908465T patent/ES2263454T3/es not_active Expired - Lifetime
2001
- 2001-09-26 US US09/964,042 patent/US20030207829A9/en not_active Abandoned
2004
- 2004-07-29 AU AU2004203458A patent/AU2004203458B2/en not_active Ceased
2010
- 2010-06-07 US US12/802,443 patent/US8318691B2/en not_active Expired - Fee Related
2012
- 2012-10-19 US US13/656,195 patent/US8772261B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8772261B2 (en)	2014-07-08
US8318691B2 (en)	2012-11-27
ATE402713T1 (de)	2008-08-15
EP1695714B1 (en)	2008-07-30
WO2000045853A2 (en)	2000-08-10
DE60039730D1 (de)	2008-09-11
AU2004203458A1 (en)	2004-08-26
DE60027870D1 (de)	2006-06-14
JP2002536347A (ja)	2002-10-29
AU2004203458B2 (en)	2007-05-17
AU772471B2 (en)	2004-04-29
US20110002890A1 (en)	2011-01-06
ES2263454T3 (es)	2006-12-16
JP4623832B2 (ja)	2011-02-02
US20030207829A9 (en)	2003-11-06
WO2000045853A3 (en)	2001-05-31
US20020019362A1 (en)	2002-02-14
EP1695714A1 (en)	2006-08-30
ATE325615T1 (de)	2006-06-15
AU2980000A (en)	2000-08-25
DE60027870T2 (de)	2006-12-28
CA2361892A1 (en)	2000-08-10
US20130039890A1 (en)	2013-02-14
EP1150696A2 (en)	2001-11-07
EP1150696B1 (en)	2006-05-10
CA2361892C (en)	2010-05-25
ES2310382T3 (es)	2009-01-01

Publication	Publication Date	Title
DK1695714T3 (da)	2008-11-10	Genetisk manipuleret herpesvirus til behandling af tumorer
LU91928I2 (fr)	2012-03-09	Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
DE69834827D1 (en)	2006-07-20	Phototherapeutische systeme
WO2004028454A3 (en)	2004-11-18	1, 3, 5-triazines for treatment of viral diseases
EP1028757A4 (en)	2002-11-27	RADIOACTIVE EMOLIZING COMPOSITIONS
NO20005342D0 (no)	2000-10-23	Belysningsapparat for fotodynamisk terapi
DK0768885T3 (da)	2004-12-06	Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
AU7380500A (en)	2001-04-17	Methods for treating tumors using neutron therapy
TR199802676A3 (tr)	1999-11-22	Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
DK1446012T3 (da)	2013-10-14	Bakteriolytisk kombinationsterapi til behandling af tumorer
EA200401124A1 (ru)	2005-02-24	Аминозамещённые (e)-2,6-диалкоксистирил-4-замещённые-бензилсульфоны для лечения пролиферативных расстройств
DK0942754T3 (da)	2003-08-04	Konjugater anvendelige til behandlingen af prostatacancer
ATE316134T1 (de)	2006-02-15	Zusammensetzung mit alpha-glycosylceramid zur stärkung zellulärer immunogenität
DK0725637T3 (da)	2001-03-26	Parenteralt busulfan til behandling af malign sygdom
NO20040516L (no)	2004-04-13	Kombinasjonsterapi for behandling av kreft.
DK1250152T3 (da)	2013-08-26	Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
MXPA03003632A (es)	2003-09-10	Metodo para tratamiento de tumores usando terapia de combinacion.
ATE306281T1 (de)	2005-10-15	Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
MXPA02007271A (es)	2004-07-30	Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales.
GB2378948B (en)	2004-11-10	Novel compounds for modulating cell proliferation
GB0120318D0 (en)	2001-10-17	System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
FI960658A7 (fi)	1996-02-14	Uudet bis-naftalimidit syövän hoitamiseksi
DK1237562T3 (da)	2005-03-14	Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE60315288D1 (de)	2007-09-13	Cyanoguanidin prodrugs
MXPA02001204A (es)	2004-05-21	Compuestos calciliticos.